Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma.
Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma.
复制标题
DOI：
10.1016/j.tvjl.2011.02.020
复制
发表时间：
2011-11-01
期刊：
影响因子：
--
通讯作者：
Iussich, Selina
中科院分区：
文献类型：
--
作者：
Mayayo, Saray Lorda;Prestigio, Simone;Iussich, Selina
硫酸软骨素蛋白聚糖-4（CSPG 4），也称为高分子量黑素瘤相关抗原（HMW-MAA），是由人黑素瘤细胞高度表达的膜结合硫酸软骨素蛋白聚糖。这种遗传学上保守的肿瘤抗原在人黑素瘤中起着重要的生物学作用，其中它被用作诊断具有不寻常特征的形式的标志物，例如促结缔组织增生性黑素瘤，并检测淋巴结和外周血中的黑素瘤细胞，并且由于其在正常组织中的有限分布而用作免疫治疗的靶标。为了鉴定合适的靶标以开发治疗犬黑素瘤的新方法，研究CSPG 4以观察其是否在犬恶性黑素瘤中表达。用抗人CSPG 4特异性抗体对65例犬恶性黑色素瘤进行免疫组化染色，37例（56.9%）检测到CSPG 4。阳性染色更频繁，虽然不显着，无黑色素性相比，黑色素性肿瘤和统计学相关的肿瘤黑色素和上皮样组织型。CSPG 4表达的频率与用作犬恶性黑素瘤的诊断标记物的其他黑素瘤抗原的频率相似，例如Melan A和由PNL 2单克隆抗体识别的蛋白质。结果表明，CSPG 4构成了一个新的潜在的免疫组化标记犬恶性黑色素瘤，并可能代表在人类的免疫靶点。
Chondroitin sulfate proteoglycan-4 (CSPG4), also known as high molecular weight-melanoma associated antigen (HMW-MAA), is a membrane-bound chondroitin sulfate proteoglycan highly expressed by human melanoma cells. This phylogenetically conserved tumour antigen plays an important biological role in human melanoma, where it is used as a marker to diagnose forms with unusual characteristics, such as desmoplastic melanoma, and to detect melanoma cells in lymph nodes and peripheral blood, and as a target for immunotherapy because of its restricted distribution in normal tissues. To identify suitable targets to develop novel approaches of treating canine melanoma, CSPG4 was studies to see whether it is expressed in canine malignant melanomas. Immunohistochemical staining of 65 canine malignant melanomas with an anti-human CSPG4-specific antibody detected CSPG4 in 37 cases (56.9%). Positive staining was more frequent, albeit not significantly, in amelanotic compared to melanotic tumours and was statistically associated with tumours having both melanin and the epithelioid histotype. The frequency of CSPG4 expression was similar to that of other melanoma antigens used as diagnostic markers for canine malignant melanoma, such as Melan A and the protein recognized by the PNL2 monoclonal antibody. The results suggest that CSPG4 constitutes a new potential immunohistochemical marker of canine malignant melanoma and may represent an immunotherapeutic target as in humans.